Pharma | Asia Healthcare Blog

Exploring the Intersection of Business, Policy and Culture, in the Asian Healthcare Space

The importance of Johnson & Johnson, Pfizer, GSK, et al., leading a ‘boycott’ of NDRC’s Request for Ex-factory Pricing

According to a report by the Beijing Daily three days ago, Johnson and Johnson, Pfizer, GSK and Harbin Pharmaceutical, are part of a ‘boycott’ of the National Development and Reform Commission’s (NDRC) latest...

by Damjan Denoble

Full Story »

Reforming How Chinese Doctors Dispense Pharmaceuticals Isn’t Going to be Easy

This was not the original topic for today’s scheduled column, but over the course of the last 24 hours between Damjan’s column yesterday on the Lin v. Siemens case and its impact on FCPA issues specific to healthcare compan...

by Benjamin

Full Story »

China’s health reforms in 2013 may be bad news for pharmaceutical companies

In today’s post I have provided a translation of a widely distributed Chinese-language article on the future of the health reforms in 2013. It features the announcements of the MOH as put forth by State Council Vice Premi...

by Damjan Denoble

Full Story »

Creative Solutions to Pharma Market Access Issues in China

For life science companies building and executing a market access strategy in China, the question is rarely whether or not a big enough market exists to justify their efforts; rather, the most pressing question is what they wil...

by Benjamin

Full Story »

The Tactics of Success for China’s Pharmaceutical Space

In Part 1 of our analysis of McKinsey’s new report on China’s healthcare reforms and what they mean to your business, we spent a good bit of time discussing the policy framework evolving in the country to expand coverage of...

by Benjamin

Full Story »